AMRN

Amarin Corporation PLC

Add to Watchlist

Advanced Chart

15.670

+0.36(2.351%)1D

Line

Candle

YTD

High

15.8515

Open

15.320

VWAP

15.46

Vol

101.71K

Mkt Cap

325.82M

Low

15.130

Amount

1.57M

EV/EBITDA(TTM)

Total Shares

410.87M

31.75M

EV/OCF(TTM)

P/S(TTM)

1.40

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

40.99M

-43.66%

0.000

-100%

42.76M

+1.78%

-0.400

-83.33%

56.92M

-8.65%

-0.430

-64.18%

Estimates Revision

The market is revising Upward the revenue expectations for Amarin Corporation plc (AMRN) for FY2025, with the revenue forecasts being adjusted by 3.66% over the past three months. During the same period, the stock price has changed by 4.12%.

Revenue Estimates for FY2025

Revise Upward

+3.66%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.31%

In Past 3 Month

Stock Price

Go Up

+4.12%

In Past 3 Month

1 Analyst Rating

-36.18% Downside

Wall Street analysts forecast AMRN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMRN is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

0 Sell

Hold

-36.18% Downside

Current: 15.670

Low

10.00

Averages

10.00

High

10.00

-36.18% Downside

Current: 15.670

Low

10.00

Averages

10.00

High

10.00

Goldman Sachs

Paul Choi

Strong Sell

Maintains

$20 → $7

2025-04-17

Reason

Goldman Sachs

Paul Choi

Price Target

$20 → $7

2025-04-17

Maintains

Strong Sell

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Amarin Corporation PLC (AMRN.O) is 382.75, compared to its 5-year average forward P/E of -25.24. For a more detailed relative valuation and DCF analysis to assess Amarin Corporation PLC 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-25.24

Current PE

382.75

Overvalued PE

23.62

Undervalued PE

-74.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-117.42

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

225.59

Undervalued EV/EBITDA

-460.43

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Overvalued

5Y Average PS

2.29

Current PS

15.31

Overvalued PS

3.78

Undervalued PS

0.81

Financials

Annual

Quarterly

FY2025Q3

YoY :

+17.43%

49.67M

Total Revenue

FY2025Q3

YoY :

-93.26%

-1.70M

Operating Profit

FY2025Q3

YoY :

-69.21%

-7.74M

Net Income after Tax

FY2025Q3

YoY :

-69.67%

-0.37

EPS - Diluted

FY2025Q3

YoY :

+438.01%

-12.70M

Free Cash Flow

FY2025Q3

YoY :

+16.19%

44.71

Gross Profit Margin - %

FY2025Q3

YoY :

+23.12%

-9.64

FCF Margin - %

FY2025Q3

YoY :

-73.78%

-15.58

Net Margin - %

FY2025Q3

N/A

ROIC

Trading Trends

Insider
Hedge Fund
Congress Trading

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

2.7K

Volume

6-9

Months

0.0

Volume

0-12

Months

3.6M

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

AMRN News & Events

Events Timeline

2025-10-29 (ET)

2025-10-29

07:08:15

Amarin announces Q3 earnings per share of 2 cents compared to a loss of 6 cents in the same period last year.

2025-10-27 (ET)

2025-10-27

08:03:58

Amarin Releases Statement Regarding Recent FDA Action on Fenofibrate Medications

2025-10-14 (ET)

2025-10-14

08:07:16

Amarin and HLS Therapeutics Unveil Mechanistic Data from REDUCE-IT Study on EPA

News

8.5

10-29NASDAQ.COM

GNTA, BBIO, AMRN Surge in After-Hours Trading: Major Biotech Factors Fueling Stock Increases

4.0

09-04NASDAQ.COM

Daily Upgrade Report for Validea Kenneth Fisher Strategy - September 4, 2025

9.0

08-30Newsfilter

New REDUCE-IT® Findings Unveiled at ESC 2025 Reveal VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Leads to 9% Decrease in Total Hospitalizations and Lowers Cardiovascular Disease Risk in Specific High-Risk Patient Groups

2025 ESC/EAS Dyslipidemia Guideline Update

High Dose Icosapent Ethyl Recommendation: The European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) reaffirmed high-dose icosapent ethyl (IPE) as a Class IIA recommended therapy for high-risk patients with elevated triglyceride levels (135–499 mg/dL) despite statin therapy, aimed at reducing cardiovascular disease (CVD) events.

REDUCE-IT Trial Insights

Impact on Cardiovascular-Kidney-Metabolic Syndrome: A post hoc analysis from the REDUCE-IT trial indicated that IPE significantly reduced cardiovascular risk in patients with cardiovascular-kidney-metabolic syndrome. In patients with an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m², IPE treatment resulted in a 44% relative risk reduction for major cardiovascular events, with a number needed to treat (NNT) of 9.
Reduction in Major Adverse Cardiovascular Events (MACE): Another analysis showed that IPE significantly reduced MACE across various baseline apolipoprotein B (ApoB) and fasting triglyceride-rich lipoprotein cholesterol (TRL-C) levels. The hazard ratios for MACE decreased progressively across quartiles of ApoB and TRL-C, indicating consistent benefits regardless of lipid levels.
Hospitalization and Mortality Effects: IPE treatment was associated with a reduction in total hospitalizations (HR 0.91) and improved survival rates without hospitalization. The odds ratio for surviving until the end of the study without hospitalization was 1.12, and the rate of days lost due to hospitalization was significantly lower (RR 0.93).

Clinical Implications

Integration into Treatment Strategies: The findings from the REDUCE-IT trial analyses support the integration of IPE into contemporary treatment strategies for high-risk patients, particularly those with complex conditions like cardiovascular-kidney-metabolic syndrome.
Robust Evidence for IPE: The consistent benefits observed across diverse patient populations reinforce the clinical utility of IPE in reducing cardiovascular risk, highlighting its potential as a complementary therapy in managing lipid-driven risks.

About Amarin and VASCEPA

Company Overview: Amarin Corporation is focused on advancing cardiovascular disease management and has offices in multiple countries. VASCEPA (icosapent ethyl) is the first FDA-approved treatment for high-risk patients with persistent cardiovascular risk despite statin therapy, launched in the U.S. in January 2020.
Market Presence: Since its launch, VASCEPA has been prescribed over 25 million times and is covered by most major medical insurance plans. It is also approved in several countries, including Canada, China, and various European nations, under the brand name VAZKEPA.